Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.16
M. A. U. Din, F. Anwer
{"title":"Luspatercept for Beta-thalassemia – A New Horizon?","authors":"M. A. U. Din, F. Anwer","doi":"10.17925/eoh.2020.16.1.16","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.16","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"2 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76232507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.14
M. A. U. Din, A. Vardag, F. Anwer
{"title":"Thromboprophylaxis – A Neglected Front in Hospitalised Patients with COVID-19 in Pakistan","authors":"M. A. U. Din, A. Vardag, F. Anwer","doi":"10.17925/eoh.2020.16.1.14","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.14","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.24
R. Leite, Isabela Demarchi, T. R. Bonatti
{"title":"Regorafenib – Five Years in Review","authors":"R. Leite, Isabela Demarchi, T. R. Bonatti","doi":"10.17925/eoh.2020.16.1.24","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.24","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.44
M. Randhawa, Robert J. Jones
{"title":"Immunotherapy in Advanced Prostate Cancer","authors":"M. Randhawa, Robert J. Jones","doi":"10.17925/eoh.2020.16.1.44","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.44","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"415 1","pages":"44"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78096965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.18
M. Aldea, B. Besse, L. Hendriks
{"title":"ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases","authors":"M. Aldea, B. Besse, L. Hendriks","doi":"10.17925/eoh.2020.16.1.18","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.18","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.39
A. D. Toma, G. Russo, D. Signorelli, R. Ferrara, A. Prelaj, G. Galli, G. Viscardi, Benedetta Trevian, M. Ganzinelli, N. Zilembo, F. Braud, M. Garassino, C. Proto
Journal Publication Date: 15 September 2020 Over the last few years, the treatment of metastatic non-small-cell lung cancer (NSCLC) has completely changed due to the advent of immunotherapy, which dramatically improved prognosis in patients without any driver alterations. First, three distinct immune checkpoint inhibitors (ICIs), nivolumab, pembrolizumab and atezolizumab, became the standard secondor later-line treatments in both squamous and non-squamous NSCLC; later pembrolizumab replaced first-line chemotherapy in advanced NSCLC characterised by programmed death ligand 1 expression of at least 50%. Based on the significant efficacy and safety results using single-agent immunotherapy, ICIs in combination with other ICIs or chemotherapy, have been largely evaluated. In particular, since 2018, several studies combining ICIs and platinum-based chemotherapy as first-line treatment showed impressive results quickly resulting in a promising new standard of care for the near future.
{"title":"Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy","authors":"A. D. Toma, G. Russo, D. Signorelli, R. Ferrara, A. Prelaj, G. Galli, G. Viscardi, Benedetta Trevian, M. Ganzinelli, N. Zilembo, F. Braud, M. Garassino, C. Proto","doi":"10.17925/eoh.2020.16.1.39","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.39","url":null,"abstract":"Journal Publication Date: 15 September 2020 Over the last few years, the treatment of metastatic non-small-cell lung cancer (NSCLC) has completely changed due to the advent of immunotherapy, which dramatically improved prognosis in patients without any driver alterations. First, three distinct immune checkpoint inhibitors (ICIs), nivolumab, pembrolizumab and atezolizumab, became the standard secondor later-line treatments in both squamous and non-squamous NSCLC; later pembrolizumab replaced first-line chemotherapy in advanced NSCLC characterised by programmed death ligand 1 expression of at least 50%. Based on the significant efficacy and safety results using single-agent immunotherapy, ICIs in combination with other ICIs or chemotherapy, have been largely evaluated. In particular, since 2018, several studies combining ICIs and platinum-based chemotherapy as first-line treatment showed impressive results quickly resulting in a promising new standard of care for the near future.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"49 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88162837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/eoh.2020.16.1.29
K. Sawada, Y. Nakamura, K. Shitara
Human epidermal growth factor receptor 2 (HER2) amplification is an important molecular mechanism underlying carcinogenesis and is associated with various types of cancer. Although the advancement of HER2-targeted therapy has been the most pronounced in breast cancer, interest has emerged in exploring the efficacy of HER2-targeted therapies in gastrointestinal (GI) cancers. In particular, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric or oesophagogastric junction cancer. Although subsequent trials involving lapatinib, ado-trastuzumab emtansine (T-DM1), and pertuzumab have failed to show significant survival benefits for HER2-positive gastric or oesophagogastric junction cancer, several trials are currently ongoing. HER2-targeted therapy has also been tested in patients with other GI cancers. Some combination therapies, such as trastuzumab plus pertuzumab, have shown promising results in single-arm phase II studies. Moreover, trials of novel anti-HER2 agents, including trastuzumab deruxtecan (T-DXd), tucatinib and margetuximab – which demonstrated improvement of clinical outcomes in breast cancer – are ongoing for GI cancers. In this review, we provide an overview of the current status of HER2-targeted therapies and focus on future perspectives for overcoming issues in the treatment of HER2-positive GI cancer.
{"title":"Development ofHER2-targeted Therapies for Gastrointestinal Cancer","authors":"K. Sawada, Y. Nakamura, K. Shitara","doi":"10.17925/eoh.2020.16.1.29","DOIUrl":"https://doi.org/10.17925/eoh.2020.16.1.29","url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2) amplification is an important molecular mechanism underlying carcinogenesis and is associated with various types of cancer. Although the advancement of HER2-targeted therapy has been the most pronounced in breast cancer, interest has emerged in exploring the efficacy of HER2-targeted therapies in gastrointestinal (GI) cancers. In particular, the addition of trastuzumab to first-line chemotherapy has improved the overall survival of patients with HER2-positive gastric or oesophagogastric junction cancer. Although subsequent trials involving lapatinib, ado-trastuzumab emtansine (T-DM1), and pertuzumab have failed to show significant survival benefits for HER2-positive gastric or oesophagogastric junction cancer, several trials are currently ongoing. HER2-targeted therapy has also been tested in patients with other GI cancers. Some combination therapies, such as trastuzumab plus pertuzumab, have shown promising results in single-arm phase II studies. Moreover, trials of novel anti-HER2 agents, including trastuzumab deruxtecan (T-DXd), tucatinib and margetuximab – which demonstrated improvement of clinical outcomes in breast cancer – are ongoing for GI cancers. In this review, we provide an overview of the current status of HER2-targeted therapies and focus on future perspectives for overcoming issues in the treatment of HER2-positive GI cancer.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"257 1","pages":"29"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91325054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-23DOI: 10.17925/eoh.2019.15.1.29
R. Coleman, J. Ledermann
{"title":"Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors","authors":"R. Coleman, J. Ledermann","doi":"10.17925/eoh.2019.15.1.29","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.1.29","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49297216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/eoh.2019.15.2.84
Sir John Burn
{"title":"Molecular Diagnostics in the Screening, Detection and Diagnosis of Cancer","authors":"Sir John Burn","doi":"10.17925/eoh.2019.15.2.84","DOIUrl":"https://doi.org/10.17925/eoh.2019.15.2.84","url":null,"abstract":"<p />","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67593184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：